Behavioral Effects of Pregabalin and Cannabis
Purpose
Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.
Condition
- Cannabis-use Disorders
Eligibility
- Eligible Ages
- Between 18 Years and 50 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- regular cannabis use - good health other than cannabis use - willingness to attempt abstinence - effective form of birth control in female subjects - available for up to 6 hrs every day for two 2-week test periods with an intervening break of 7-10 days each - located in close proximity to University of Kentucky
Exclusion Criteria
- medical screening outcomes outside normal ranges or deemed clinically insignificant - medical history that would contraindicate pregabalin administration
Study Design
- Phase
- Early Phase 1
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover Assignment
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Pregabalin 1 |
Dose 1 |
|
Placebo Comparator Placebo 1 |
Placebo 1 |
|
Experimental Pregabalin 2 |
Dose 2 |
|
Placebo Comparator Placebo 2 |
Placebo 2 |
|
Recruiting Locations
More Details
- NCT ID
- NCT01511640
- Status
- Completed
- Sponsor
- Joshua A. Lile, Ph.D.